The Food and Drug Administration (FDA) in the U.S. granted approval to the world’s first vaccine for chikungunya on November 9.
Ixchiq – World’s First Vaccine for Chikungunya
Manufacturer: Valneva (European)
Vaccine Name: Ixchiq
Eligibility: Individuals aged 18 or older at an increased risk of chikungunya exposure.
Vaccine Administration:
Dosage: Single-dose injection into the muscle.
Composition: Live, weakened chikungunya virus.
Live-Attenuated Vaccines
These differ from traditional inactivated vaccines where the pathogen is “killed”.
As the name suggests the pathogen (typically a virus) remains active in live vaccines, however, is attenuated or modified in a way that the pathogen is not able to cause disease itself but can produce a robust immune response.
About Chikungunya Disease:
Chikungunya disease, is characterised by severe joint pain and impaired mobility, and comes with fever.
Transmission: It is a viral infection (CHIKV) transmitted primarily by the Aedes aegypti and Aedes albopictus mosquitoes and has been described as “an emerging global health threat.”
Treatment: As of now, there is no cure, only symptomatic relief, with analgesics to help with the pain, antipyretics for the fever, rest, and adequate fluids.
Prevention: It includes mosquito control activities.
Prevalent of Chikungunya: Brazil, Paraguay, India (as per the National Centre for Vector Borne Diseases Control, India had 93,455 suspected chikungunya cases until September in 2023), and parts of western Africa.
Comprehensive coverage with a concise format Integration of PYQ within the booklet Designed as per recent trends of Prelims questions हिंदी में भी उपलब्ध
Quick Revise Now ! UDAAN PRELIMS WALLAH
Comprehensive coverage with a concise format Integration of PYQ within the booklet Designed as per recent trends of Prelims questions हिंदी में भी उपलब्ध
<div class="new-fform">
</div>
Subscribe our Newsletter
Sign up now for our exclusive newsletter and be the first to know about our latest Initiatives, Quality Content, and much more.